14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
In late 2017, the NLRB in Boeing Company, 365 NLRB No. 154 (2017), established a new three category ...
Read More >
Non-essential in-person activities have been restricted in New York State during the ongoing COVID-1...
Read More >
The City of Duluth, Minnesota’s Earned Sick and Safe Time Ordinance (ESST) will go into effect on J...
Read More >
In Gainesville Mechanical, Inc. v. Air Data, Inc., --- S.E.2d ---- (June 19, 2019), the Georgia Cour...
Read More >
In early May, the Massachusetts Supreme Judicial Court held that 100% commission-based inside salesp...
Read More >
In a decision of great interest in the M&A world, the Delaware Chancery Court recently ruled that a ...
Read More >